Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,800 GBX | +1.07% | +3.81% | +24.09% |
May. 08 | Gsk plc Announces Board Committee Changes | CI |
May. 08 | GSK : Receives a Buy rating from Bernstein | ZD |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Over the past four months, analysts' average price target has been revised upwards significantly.
- Analyst opinion has improved significantly over the past four months.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+24.09% | 90.86B | B | ||
+31.15% | 695B | C+ | ||
+26.51% | 568B | B | ||
-4.62% | 361B | C+ | ||
+19.69% | 330B | B- | ||
+3.70% | 283B | C+ | ||
+16.70% | 239B | B+ | ||
+8.78% | 204B | B- | ||
-7.93% | 198B | A+ | ||
+9.08% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- GSK Stock
- Ratings GSK plc